Pediatrix Medical Group, Inc.
New York Stock ExchangeRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Pediatrix Medical Group, Inc. (NYSE: MD) is a physician-led provider of specialized health care services for women, babies, and children across the United States. The company offers maternal-fetal medicine, obstetrical hospitalist services, obstetrics and gynecology care; neonatology including neonatal intensive care units (NICUs), newborn nursery services, and newborn hearing screens; and more than 20 pediatric subspecialties such as cardiology, pulmonology, neurology, gastroenterology, hematology, infectious disease, intensive/critical care, emergency medicine, surgery, and hospitalist services; complemented by telemedicine solutions, telehealth, and evidence-based clinical research support. Pediatrix-affiliated clinicians, numbering approximately 4,400 including over 2,600 physicians, deliver coordinated care in hospital settings and office-based practices, partnering with nearly 400 hospitals and health systems across 36 to 37 states. Founded in 1979 and headquartered in Sunrise, Florida, the company focuses on high-quality, patient-centered outcomes through investments in research, education, quality improvement, safety initiatives, and advanced clinical data utilization. In recent strategic developments, Pediatrix completed a portfolio restructuring in 2024-2025 by divesting its anesthesiology and radiology medical groups as well as its primary and urgent care clinics to refocus on core hospital-based services in neonatology, maternal-fetal medicine, pediatric intensive care, and obstetrics. The company transitioned to a hybrid revenue cycle management model, enhancing collection activity and operational efficiency, which contributed to improved free operating cash flow of $147 million and reduced leverage to 1.1x as of September 30, 2025. Additional changes include leadership transitions with Jim D. Swift, M.D., as CEO, a $250 million share repurchase authorization in August 2025, an S&P credit rating upgrade to 'BB' in November 2025, and raised full-year adjusted EBITDA guidance to $270-$290 million amid targeted small acquisitions in NICUs, maternal-fetal medicine, and obstetric hospitalist operations. These initiatives support same-unit revenue growth of 6.9% year-to-date in 2025 and position the company for low-single-digit volume expansion and modest reimbursement increases.
Allspring Global Investments Holdings LLC Acquires 335,733 Shares of Pediatrix Medical Group, Inc. $MD
Pediatrix Medical Group, Inc. (NYSE:MD) Receives Consensus Rating of “Hold” from Analysts
Pediatrix Medical Group (MD) Soars 7.3%: Is Further Upside Left in the Stock?
Why Pediatrix Medical Group (MD) is a Top Growth Stock for the Long-Term
Pediatrix Medical Group Provides Second Quarter Update
Why Pediatrix Medical Group (MD) is a Top Momentum Stock for the Long-Term
Pediatrix Medical Group (MD) is a Top-Ranked Growth Stock: Should You Buy?
Here's Why Pediatrix Medical Group (MD) is a Strong Momentum Stock
New CV APP Compensation and Utilization Survey Report Highlights Growing APP Contributions, Prompting Focus on Support and Compensation
Maryland Public Television earns 20 regional Emmy® Awards
New Anglia University Responds to Rising Competition for Medical School Places in the UK
Onera Will Showcase Its Onera hPSG® Solution at the SLEEP 2026 Conference June 14-17, 2026 in Baltimore, MD, USA.
Here's Why Pediatrix Medical Group (MD) is a Strong Growth Stock
Tempest Therapeutics Appoints Drake Richey and John Yee, MD, MPH to Board of Directors
Why Is Pediatrix Medical Group (MD) Down 1.7% Since Last Earnings Report?
Pediatrix Medical Group Announces Publication of New Research Addressing Urgent Questions in Neonatology
HSS Chief of Sports Medicine, Riley J. Williams III, MD, Named FIFA Venue Medical Officer for the 2026 World Cup
Here's Why Pediatrix Medical Group (MD) is a Strong Growth Stock
Vistagen Appoints Angel S. Angelov, MD, MBA, as Chief Medical Officer
Passkey Therapeutics Appoints Mandeep Kaur, MD, MS, as Chief Medical Officer to Advance Clinical Validation of Its Computational Genetics-Based Novel Drug Combination Platform